Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats

Transplantation

Volumn 93, Issue 3, 2012, Pages 249-256

  Pech, Thomas ^a   Fujishiro, Jun ^a,b,c   Finger, Tobias ^a   Ohsawa, Ichiro ^a,d   Praktiknjo, Michael ^a   Abu Elmagd, Kareem ^e   Von Websky, Martin ^a   Overhaus, Marcus ^a   Kalff, Joerg C ^a   Schaefer, Nico ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acute rejection; Infliximab; Motility; Small bowel transplantation; Tacrolimus

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINAL DYSMOTILITY; INTESTINE MUSCLE; INTESTINE TRANSPLANTATION; MACROPHAGE; MONOCYTE; MUSCLE FUNCTION; NEUTROPHIL; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TREATMENT RESPONSE;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CHEMOKINES; CYTOKINES; DRUG THERAPY, COMBINATION; GASTROINTESTINAL MOTILITY; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTESTINE, SMALL; MACROPHAGES; NEUTROPHIL INFILTRATION; RATS; RATS, INBRED BN; RATS, INBRED LEW; TACROLIMUS;

EID: 84856494123     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823e7abb     Document Type: Article

References (43)

1. Pondrom S. The AJT Report Survival rates increase in bowel transplantation: Seldom-done procedure comes of age.AmJ Transplant 2010; 10: 438.
2. Fishbein TM. Intestinal transplantation. N Engl J Med 2009; 361: 998.
3. Abu-Elmagd KM, Costa G, Bond GJ, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int 2009; 22: 96.
4. Pascher A, Kohler S, Neuhaus P, et al. Present status and future perspectives of intestinal transplantation. Transpl Int 2008; 21: 401.
5. Fishbein T, Novitskiy G, Mishra L, et al. NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 2008; 57: 323.
6. Janse M, Weersma RK, Sudan DL, et al. Association of Crohn's diseaseassociated NOD2 variants with intestinal failure requiring small bowel transplantation and clinical outcomes. Gut 2010; 60: 877.
7. Ningappa M, Higgs BW, Weeks DE, et al. NOD2 gene polymorphism rs2066844 associates with need for combined liver-intestine transplantation in children with short-gut syndrome. Am J Gastroenterol 2010; 106: 157.
8. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort. Gut 2009; 58: 492.
9. Schaefer N, Tahara K, Websky M, et al. Acute rejection in allogeneic rodent small bowel transplantation causes smooth muscle dysfunction via an inflammatory response within the intestinal muscularis. Transplant Proc 2006; 38: 1792.
10. Schaefer N, Tahara K, Websky MV, et al. Acute rejection and the muscularis propria after intestinal transplantation: The alloresponse, inflammation, and smooth muscle function. Transplantation 2008; 85: 1465.
11. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189.
12. Quan D, Grant DR, Zhong RZ, et al. Altered gene expression of cytokine, ICAM-1, and class II molecules precedes mouse intestinal allograft rejection. Transplantation 1994; 58: 808.
13. Wiggins MC, Bracher M, Mall A, et al. Tumour necrosis factor levels during acute rejection and acute tubular necrosis in renal transplant recipients. Transpl Immunol 2000; 8: 211.
14. Farmer DG, McDiarmid SV, Kuniyoshi J, et al. Intragraft expression of messenger RNA for interleukin-6 and tumor necrosis factor-alpha is a predictor of rat small intestine transplant rejection. J Surg Res 1994; 57: 138.
15. Pascher A, Klupp J, Langrehr JM, et al. Anti-TNF-alpha therapy for acute rejection in intestinal transplantation. Transplant Proc 2005; 37: 1635.
16. Pascher A, Radke C, Dignass A, et al. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. Transplantation 2003; 76: 615.
17. Pirenne J, Kawai M. Intestinal transplantation: Evolution in immunosuppression protocols. Curr Opin Organ Transplant 2009; 14: 250.
18. Rodriguez V, Anderson PM, Trotz BA, et al. Use of infliximabdaclizumab combination for the treatment of acute and chronic graftversus- host disease of the liver and gut. Pediatr Blood Cancer 2007; 49: 212.
19. Gerlach UA, Koch M, Muller HP, et al. Tumor necrosis factor alpha inhibitors as immunomodulatory antirejection agents after intestinal transplantation. Am J Transplant 2011; 11: 1041.
20. De Greef E, Avitzur Y, Grant D, et al. The successful use of infliximab as salvage therapy in pediatric intestinal transplant patients with steroid and thymoglobulin resistant late acute rejection. J Pediatr Gastroenterol Nutr [published online ahead of print June 17, 2011] doi:10.1097/MPG. 0b013e3182293d73.
21. Pech T, Finger T, Fujishiro J, et al. Perioperative infliximab application ameliorates acute rejection associated inflammation after intestinal transplantation. Am J Transplant 2010; 10: 2431.
22. Wyburn KR, Jose MD,WuH, et al. The role of macrophages in allograft rejection. Transplantation 2005; 80: 1641.
23. Schaefer N, Tahara K, von WM, et al. Role of resident macrophages in the immunologic response and smooth muscle dysfunction during acute allograft rejection after intestinal transplantation. Transpl Int 2008; 21: 778.
24. Türler A, Schwarz NT, Turler E, et al. MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002; 282: G145.
25. Schaefer N, Tahara K, Schmidt J, et al. Mechanism and impact of organ harvesting and ischemia-reperfusion injury within the graft muscularis in rat small bowel transplantation. Transplant Proc 2006; 38: 1821.
26. Schaefer N, Tahara K, Schmidt J, et al. Resident macrophages are involved in intestinal transplantation-associated inflammation and motoric dysfunction of the graft muscularis. Am J Transplant 2007; 7: 1062.
27. Schaefer N, Tahara K, Schuchtrup S, et al. Perioperative glycine treatment attenuates ischemia/reperfusion injury and ameliorates smooth muscle dysfunction in intestinal transplantation. Transplantation 2008; 85: 1300.
28. Schaefer N, Tahara K, Pech T, et al. Inducible nitric oxide synthase expression in the intestinal muscularis mediates severe smooth muscle dysfunction during acute rejection in allogenic rodent small bowel transplantation. J Surg Res 2008; 150: 159.
29. Schwarz NT, Kalff JC, Türler A, et al. Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus. Gastroenterology 2001; 121: 1354.
30. Fujishiro J, Pech TC, Finger TF, et al. Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. Am J Transplant 2010; 10: 1545.
31. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
32. Kingsley CI, Karim M, Bushell AR, et al. CD25-CD4- regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080.
33. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995.
34. Rutgeerts P, Van AG, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593.
35. He H, Stone JR, Perkins DL. Analysis of differential immune responses induced by innate and adaptive immunity following transplantation. Immunology 2003; 109: 185.
36. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferongamma: Implications for immune responses and autoimmune diseases. Immunity 2009; 31: 539.
37. HuX, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008; 226: 41.
38. Hummel M, Kurian SM, Lin S, et al. Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation 2009; 87: 178.
39. Schwarz NT, Nakao A, Nalesnik MA, et al. Protective effects of ex vivo graft radiation and tacrolimus on syngeneic transplanted rat small bowel motility. Surgery 2002; 131: 413.
40. Murase N, Demetris AJ, Woo J, et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation 1993; 55: 1.
41. Roskott AM, Nieuwenhuijs VB, Dijkstra G, et al. Small bowel preservation for intestinal transplantation: A review. Transpl Int 2011; 24: 107.
42. WuT, Abu-Elmagd K, Bond G, et al. A schema for histologic grading of small intestine allograft acute rejection. Transplantation 2003; 75: 1241.
43. Kalff JC, Schraut WH, Simmons RL, et al. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg 1998; 228: 652.